Prof. Suneil Jain (Queen's University Belfast) and Prof. Michael Zelefsky (Memorial Sloan Kettering Cancer Center in Manhattan) share their experience and deep dive into the spacer placement and a spacer quality score, based on a poster publication from Prof. Zelefsky and Dr. Timmerman at ASTRO 2021.
Disclaimer: Results from different clinical investigations are not directly comparable. Information provided for educational purposes only. SpaceOAR and SpaceOAR Vue Hydrogels are intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR and SpaceOAR Vue Hydrogels to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue Hydrogels contain polyethylene glycol (PEG). SpaceOAR Vue Hydrogel contains iodine. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. As with any medical treatment, there are some risks involved with the use of SpaceOAR and SpaceOAR Vue Hydrogels. Potential complications associated with SpaceOAR and SpaceOAR Vue Hydrogels include, but are not limited to: pain associated with SpaceOAR and SpaceOAR Vue Hydrogels injection, pain or discomfort associated with SpaceOAR and SpaceOAR Vue Hydrogels, local inflammatory reactions, infection (including abscess), urinary retention, urgency, constipation (acute, chronic, or secondary to outlet perforation), rectal tenesmus/muscle spasm, mucosal damage, ulcers, fistula, perforation (including prostate, bladder, urethra, rectum), necrosis, allergic reaction (localized or more severe reaction, such as anaphylaxis), embolism (venous or arterial embolism is possible and may present outside of the pelvis, potentially impacting vital organs or extremities), syncope and bleeding. The occurrence of one or more of these complications may require treatment or surgical intervention.
URO-989811-AB.
CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Information for use only in countries with applicable health authority registrations. This material not intended for use in France.
IMPORTANT INFORMATION:
“The information about patient selection is specific to Dr. Zelefsky’s practice only. In Canada SpaceOAR hydrogel is only approved to be used in prostate cancer patients without evidence of posterior extracapsular extension. In the US pivotal trial, patients with extracapsular extension and previous pelvic irradiation were excluded.” The information about patient selection is specific to Dr. Jain’s practice only. In Canada SpaceOAR hydrogel is only approved to be used in prostate cancer patients without evidence of posterior extracapsular extension. In the US pivotal trial, patients with extracapsular extension and previous pelvic irradiation were excluded.” “The information provided is based on the experiences of Dr. Zelefsky and Dr. Jain and does not represent the opinion or recommendation of BSC.” BSC does not promote or encourage the use of its devices outside their approved labeling. The presenter’s experience with BSC products may not be interpreted or relied upon to support clinical claims about BSC devices or product comparison claims regarding BSC and competitive devices. The experiences of other users may vary. This presentation contains several case studies. Results from case studies are not predictive of results in other cases. Results in other cases may vary. Regarding the publications referenced in this presentation are for information purposes only. The content of these articles are under the sole responsibility of the authors/publishers and does not represent the opinions of BSC.
